Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review
Research output: Contribution to journal › Review › Research › peer-review
Standard
Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review. / Zeriouh, Mariam; Raskov, Hans; Kvich, Lasse; Gögenur, Ismail; Bennedsen, Astrid Louise Bjørn.
In: Neoplasia (United States), Vol. 43, 100923, 2023.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review
AU - Zeriouh, Mariam
AU - Raskov, Hans
AU - Kvich, Lasse
AU - Gögenur, Ismail
AU - Bennedsen, Astrid Louise Bjørn
N1 - Publisher Copyright: © 2023
PY - 2023
Y1 - 2023
N2 - Background: Evidence suggests that the human gut microbiota modulates the treatment response of immune checkpoint inhibitors (ICI) in cancer. Thus, finding predictive biomarkers in the fecal gut microbiota of patients who are less likely to respond to ICI would be valuable. This systematic review aimed to investigate the association between fecal gut microbiota composition and ICI-treatment response in patients with cancer. Methods: EMBASE, Medline, and Cochrane Library databases were searched using the "Participants, Interventions, Comparisons, and Outcomes" (PICO) process to locate studies including participants with solid cancers treated with ICI intervention. The comparator was the gut microbiota, and the outcomes were oncological outcomes such as response rates and progression-free survival. Study data were synthesized qualitatively in a systematic narrative synthesis, and the risk of bias in the studies was assessed. Results: Two reviewers screened 2092 abstracts independently, and 140 studies were read as full-text reports and assessed for eligibility. Eighteen studies were included with 775 patients with different types of solid cancers who received anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. Distinct patterns were observed in the patients' fecal samples. Some bacterial species were reported to be present in responders and non-responders, while others were present only in one group. The most reported species associated with better prognosis were Faecalibacterium prausnitzii, Streptococcus parasanguinis, Bacteroides caccae, and Prevotella copri. In contrast, the most reported species associated with poor prognosis were Blautia obeum and Bacteroides ovatus. Conclusion: Distinct microbiota features were associated with good and poor prognoses in ICI-treated patients with cancer.
AB - Background: Evidence suggests that the human gut microbiota modulates the treatment response of immune checkpoint inhibitors (ICI) in cancer. Thus, finding predictive biomarkers in the fecal gut microbiota of patients who are less likely to respond to ICI would be valuable. This systematic review aimed to investigate the association between fecal gut microbiota composition and ICI-treatment response in patients with cancer. Methods: EMBASE, Medline, and Cochrane Library databases were searched using the "Participants, Interventions, Comparisons, and Outcomes" (PICO) process to locate studies including participants with solid cancers treated with ICI intervention. The comparator was the gut microbiota, and the outcomes were oncological outcomes such as response rates and progression-free survival. Study data were synthesized qualitatively in a systematic narrative synthesis, and the risk of bias in the studies was assessed. Results: Two reviewers screened 2092 abstracts independently, and 140 studies were read as full-text reports and assessed for eligibility. Eighteen studies were included with 775 patients with different types of solid cancers who received anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. Distinct patterns were observed in the patients' fecal samples. Some bacterial species were reported to be present in responders and non-responders, while others were present only in one group. The most reported species associated with better prognosis were Faecalibacterium prausnitzii, Streptococcus parasanguinis, Bacteroides caccae, and Prevotella copri. In contrast, the most reported species associated with poor prognosis were Blautia obeum and Bacteroides ovatus. Conclusion: Distinct microbiota features were associated with good and poor prognoses in ICI-treated patients with cancer.
KW - Anti-CTLA-4
KW - Anti-PD-1
KW - Anti-PD-L1
KW - Cancer
KW - Fecal gut microbiota
KW - Immune checkpoint inhibitors
U2 - 10.1016/j.neo.2023.100923
DO - 10.1016/j.neo.2023.100923
M3 - Review
C2 - 37603952
AN - SCOPUS:85168754956
VL - 43
JO - Neoplasia
JF - Neoplasia
SN - 1522-8002
M1 - 100923
ER -
ID: 365824987